{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Capillary+Malformation",
    "query": {
      "condition": "Capillary Malformation"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 29,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Capillary+Malformation&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T05:07:49.779Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00975819",
      "title": "Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kaposiform Hemangioendotheliomas",
        "Tufted Angioma",
        "Capillary Venous Lymphatic Malformation",
        "Venous Lymphatic Malformation",
        "Microcystic Lymphatic Malformation",
        "Mucocutaneous Lymphangiomatosis and Thrombocytopenia",
        "Capillary Lymphatic Arterial Venous Malformations",
        "PTEN Overgrowth Syndrome With Vascular Anomaly",
        "Lymphangiectasia Syndromes"
      ],
      "interventions": [
        {
          "name": "sirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Denise Martin Adams",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "31 Years",
        "sex": "ALL",
        "summary": "Up to 31 Years"
      },
      "enrollment_count": 61,
      "start_date": "2009-10",
      "completion_date": "2020-10",
      "has_results": true,
      "last_update_posted_date": "2026-01-06",
      "last_synced_at": "2026-05-22T05:07:49.779Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Cincinnati, Ohio",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00975819"
    },
    {
      "nct_id": "NCT01431326",
      "title": "Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Adenovirus",
        "Anesthesia",
        "Anxiety",
        "Anxiolysis",
        "Autism",
        "Autistic Disorder",
        "Bacterial Meningitis",
        "Bacterial Septicemia",
        "Benzodiazepine",
        "Bipolar Disorder",
        "Bone and Joint Infections",
        "Central Nervous System Infections",
        "Convulsions",
        "Cytomegalovirus Retinitis",
        "Early-onset Schizophrenia Spectrum Disorders",
        "Epilepsy",
        "General Anesthesia",
        "Gynecologic Infections",
        "Herpes Simplex Virus",
        "Infantile Hemangioma",
        "Infection",
        "Inflammation",
        "Inflammatory Conditions",
        "Intra-abdominal Infections",
        "Lower Respiratory Tract Infections",
        "Migraines",
        "Pain",
        "Pneumonia",
        "Schizophrenia",
        "Sedation",
        "Seizures",
        "Skeletal Muscle Spasms",
        "Skin and Skin-structure Infections",
        "Treatment-resistant Schizophrenia",
        "Urinary Tract Infections",
        "Withdrawal",
        "Sepsis",
        "Gram-negative Infection",
        "Bradycardia",
        "Cardiac Arrest",
        "Cardiac Arrhythmia",
        "Staphylococcal Infections",
        "Nosocomial Pneumonia",
        "Neuromuscular Blockade",
        "Methicillin Resistant Staphylococcus Aureus",
        "Endocarditis",
        "Neutropenia",
        "Headache",
        "Fibrinolytic Bleeding",
        "Pulmonary Arterial Hypertension",
        "CMV Retinitis",
        "Hypertension",
        "Chronic Kidney Diseases",
        "Hyperaldosteronism",
        "Hypokalemia",
        "Heart Failure",
        "Hemophilia",
        "Heavy Menstrual Bleeding",
        "Insomnia"
      ],
      "interventions": [
        {
          "name": "The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daniel Benjamin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 3520,
      "start_date": "2011-11",
      "completion_date": "2019-11",
      "has_results": false,
      "last_update_posted_date": "2023-09-06",
      "last_synced_at": "2026-05-22T05:07:49.779Z",
      "location_count": 43,
      "location_summary": "Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01431326"
    },
    {
      "nct_id": "NCT00556946",
      "title": "Combined Photodynamic and Pulsed Dye Laser Treatment of Port Wine Stains",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Port Wine Stains"
      ],
      "interventions": [
        {
          "name": "Combined Photodynamic & Pulsed Dye Laser Treatment",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Irvine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2005-08",
      "completion_date": "2014-10",
      "has_results": true,
      "last_update_posted_date": "2022-10-21",
      "last_synced_at": "2026-05-22T05:07:49.779Z",
      "location_count": 1,
      "location_summary": "Irvine, California",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00556946"
    },
    {
      "nct_id": "NCT06237153",
      "title": "Randomized Placebo Controlled Study of Triamcinolone Acetonide Extended Release Injection for Thumb (CMC) Osteoarthritis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Carpometacarpal (CMC) Osteoarthritis"
      ],
      "interventions": [
        {
          "name": "Triamcinolone Acetonide extended release suspension",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Marie Badalamente",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2023-11-21",
      "completion_date": "2025-12-31",
      "has_results": false,
      "last_update_posted_date": "2024-02-01",
      "last_synced_at": "2026-05-22T05:07:49.779Z",
      "location_count": 1,
      "location_summary": "Stony Brook, New York",
      "locations": [
        {
          "city": "Stony Brook",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06237153"
    },
    {
      "nct_id": "NCT03652181",
      "title": "CASH (Cavernous Angiomas With Symptomatic Hemorrhage) Trial Readiness",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "CCM",
        "Cavernoma",
        "Cerebral Cavernous Malformation",
        "Cerebral Cavernous Malformations 1",
        "Cerebral Cavernous Malformations 2",
        "Cerebral Cavernous Malformations 3",
        "Cavernous Angioma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 123,
      "start_date": "2018-08-20",
      "completion_date": "2022-11-03",
      "has_results": true,
      "last_update_posted_date": "2024-06-27",
      "last_synced_at": "2026-05-22T05:07:49.779Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03652181"
    },
    {
      "nct_id": "NCT04125290",
      "title": "US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI)",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hairy Cell Leukemia"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 2,
      "start_date": "2019-12-09",
      "completion_date": "2021-06-21",
      "has_results": false,
      "last_update_posted_date": "2025-07-18",
      "last_synced_at": "2026-05-22T05:07:49.779Z",
      "location_count": 2,
      "location_summary": "Pueblo, Colorado • Bridgeton, Missouri",
      "locations": [
        {
          "city": "Pueblo",
          "state": "Colorado"
        },
        {
          "city": "Bridgeton",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04125290"
    },
    {
      "nct_id": "NCT00330564",
      "title": "Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Von Hippel-Lindau Syndrome",
        "Renal Cell Carcinoma",
        "Hemangioblastoma"
      ],
      "interventions": [
        {
          "name": "SU011248",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2006-05",
      "completion_date": "2011-05",
      "has_results": true,
      "last_update_posted_date": "2024-06-27",
      "last_synced_at": "2026-05-22T05:07:49.779Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00330564"
    },
    {
      "nct_id": "NCT02859441",
      "title": "A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Von Hippel-Lindau Syndrome"
      ],
      "interventions": [
        {
          "name": "Ranibizumab",
          "type": "DRUG"
        },
        {
          "name": "E10030",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Eye Institute (NEI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2017-01-23",
      "completion_date": "2019-07-09",
      "has_results": true,
      "last_update_posted_date": "2021-11-01",
      "last_synced_at": "2026-05-22T05:07:49.779Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02859441"
    },
    {
      "nct_id": "NCT00589784",
      "title": "Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "CNS Cancer",
        "Meningioma",
        "Intracranial Hemangiopericytoma",
        "Hemangioblastoma",
        "Neurofibromatosis"
      ],
      "interventions": [
        {
          "name": "Sunitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2007-10",
      "completion_date": "2014-10",
      "has_results": true,
      "last_update_posted_date": "2016-01-25",
      "last_synced_at": "2026-05-22T05:07:49.779Z",
      "location_count": 6,
      "location_summary": "Boston, Massachusetts • Basking Ridge, New Jersey • Commack, New York + 3 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00589784"
    },
    {
      "nct_id": "NCT01408056",
      "title": "Timolol Option for Ulcerated Hemangiomas (TOUCH Trial)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Infantile Hemangiomas"
      ],
      "interventions": [
        {
          "name": "Timolol 0.5% Gel Forming Solution (GFS)",
          "type": "DRUG"
        },
        {
          "name": "Mupirocin 2% Ointment",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Hospital of Philadelphia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "8 Months",
        "sex": "ALL",
        "summary": "1 Month to 8 Months"
      },
      "enrollment_count": 0,
      "start_date": "2011-02",
      "completion_date": "2014-01",
      "has_results": false,
      "last_update_posted_date": "2014-01-17",
      "last_synced_at": "2026-05-22T05:07:49.779Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01408056"
    }
  ]
}